Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Jul 25, 2025-

CHMP endorses Pfizer-BioNTech's updated Covid-19 vaccine

This updated vaccine is aimed at individuals aged six months and older. The CHMP’s endorsement is based on a comprehensive body of evidence, including clinical, non-clinical, and real-world The post CHMP endorses Pfizer-BioNTech’s updated Covid-19 vaccine appeared first on Pharmaceutical Business review.

EMA Recommends Approval of Pfizer-BioNTech’s LP.8.1 COVID-19 Vaccine for Broad Use in EU

Open the article to view the coverage from EuropaWire.eu

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulations Upon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and older To date, […] The post Pfizer and BioNTech Receive Positive CHMP …

Pfizer's Latest COVID Vaccine Shows Enhanced Protection Against XFG and NB.1.8.1 Variants

Advanced LP.8.1-adapted vaccine demonstrates superior immune response against emerging variants. Ready for immediate EU distribution upon final approval. See efficacy data.